Investors News Year 2022 2021 2020 2019 2018 2022 BioGraphene 4/19/22 2022 BioGraphene 4/19/22 BioGraphene Appoints Dr. Daehee Kang as Medical Advisor Read More 2022 BioGraphene 3/31/22 2022 BioGraphene 3/31/22 BioGraphene Presented at the 10th Annual Neurodegenerative Drug Development Summit Read More 2022 BioGraphene 3/22/22 2022 BioGraphene 3/22/22 BioGraphene Signs Patent License Agreement with Seoul National University and Johns Hopkins University Read More 2022 BioGraphene 1/3/22 2022 BioGraphene 1/3/22 BioGraphene Signs Collaboration Agreement with Dr. Paulina Ordonez for BGN-112’s Pharmacodynamic Study Read More 2021 BioGraphene 11/5/21 2021 BioGraphene 11/5/21 BioGraphene Signs Collaborative Research Agreement with Dong-A University for the Efficacy Study of Graphene Quantum Dots in ALS Read More Newer Posts Older Posts
2022 BioGraphene 4/19/22 2022 BioGraphene 4/19/22 BioGraphene Appoints Dr. Daehee Kang as Medical Advisor Read More
2022 BioGraphene 3/31/22 2022 BioGraphene 3/31/22 BioGraphene Presented at the 10th Annual Neurodegenerative Drug Development Summit Read More
2022 BioGraphene 3/22/22 2022 BioGraphene 3/22/22 BioGraphene Signs Patent License Agreement with Seoul National University and Johns Hopkins University Read More
2022 BioGraphene 1/3/22 2022 BioGraphene 1/3/22 BioGraphene Signs Collaboration Agreement with Dr. Paulina Ordonez for BGN-112’s Pharmacodynamic Study Read More
2021 BioGraphene 11/5/21 2021 BioGraphene 11/5/21 BioGraphene Signs Collaborative Research Agreement with Dong-A University for the Efficacy Study of Graphene Quantum Dots in ALS Read More
